Brief: Gen Ilac Signs Alternative Reimbursement Contract With SGK For SMA Drug Named As "Spinraza"

Gen Ilac ve Saglik Urunleri Sanayi Ticaret

10/08/2023 14:32

Aug 10 (Reuters) - Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS  GENIL.IS :
    * ALTERNATIVE REIMBURSEMENT CONTRACT SIGNED BETWEEN SOCIAL SECURITY INSTITUTION OF TÜRKIYE
("SGK")
AND OUR COMPANY FOR SMA DRUG NAMED AS "SPINRAZA"
    * EFFECTIVE DATE OF CONTRACT IS 10.08.2023, AND CONTRACT TO END WITH SUPPLY OF NUMBER OF
DRUGS
SPECIFIED IN THE CONTRACT TO SGK
    * EXPECTS CONRITBUTION OF THIS CONTRACT TO 2023 TOTAL SALES WOULD BE BETWEEN 700-750 MILLION
LIRA

Source text for Eikon:  ID:nIKA1ysPBH 
Further company coverage:  GENIL.IS 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))